CADENCE PHARMACEUTICALS INC

Operating margin

−116.7%

Net margin

−5.8%

Return on equity

−3.9%

Return on assets

−1.5%

Return on capital (ROCE)

−50.8%

Liabilities / assets

61.6%

Debt / equity

1.60×

Book value / share

$0.41

Revenue growth (YoY)

195.0%

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

-15.34distress

Accruals / assets

24.0%high accruals

Piotroski F-Score

3/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 19, 2014
• Results of operationsFeb 28, 2014
• Director / officer changeFeb 28, 2014
• Entered a material agreement · Amended charter or bylaws · Other material eventFeb 11, 2014
• Entered a material agreementJan 30, 2014
• Results of operations · Other material eventJan 13, 2014
• Regulation FD disclosure · Other material eventDec 16, 2013
• Director / officer changeNov 26, 2013

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.